Results 1 to 10 of about 756,046 (308)

Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease [PDF]

open access: yesMediators of Inflammation, 1998
Mesalazine is widely used in the treatment of inflammatory bowel disease. Little is known about the doseresponse relationship and about possible dose related side effects.
C. J. J. Mulder, S. J. Van Den Hazel
doaj   +3 more sources

Different beta-blockers for preventing arrhythmic events in patients with long QT syndrome: a network meta-analysis [PDF]

open access: yesFrontiers in Medicine
ObjectiveThis study aims to compare the efficacy of different types of beta-blockers in preventing arrhythmias in patients with long QT syndrome (LQTS), and simultaneously analyze the relationship between dose and effect within each drug by incorporating
Youxu Jiang   +6 more
doaj   +2 more sources

Evaluating the relationship between Ex3 vNTR and rs3758653 polymorphisms in DRD4 genes in children with attention deficit hyperactivity disorder with respect to the dose of methylphenidate [PDF]

open access: yesمجله پزشکی دانشگاه علوم پزشکی تبریز, 2022
Background. Attention deficit hyperactivity disorder (ADHD) is one of the most common psychiatric disorders starting at an early age with symptoms of attention deficit hyperactivity disorder and impulsivity.
Shahrokh Amiri   +5 more
doaj   +1 more source

Adverse effects of long term, continual administration of high doses of albendazole in the treatment of echinococcal disease [PDF]

open access: yesVojnosanitetski Pregled, 2008
Background/Aim. Modern treatment of cystic echinococcosis, except for surgical treatment and percutaneous drainage of cyst considers also administration of albendazole as a type of individual therapy.
Jevtić Miodrag   +6 more
doaj   +1 more source

drexplorer: A tool to explore dose–response relationships and drug–drug interactions [PDF]

open access: yesBioinformatics, 2015
AbstractMotivation: Nonlinear dose–response models are primary tools for estimating the potency [e.g. half-maximum inhibitory concentration (IC) known as IC50] of anti-cancer drugs. We present drexplorer software, which enables biologists to evaluate replicate reproducibility, detect outlier data points, fit different models, select the best model ...
Pan, Tong   +8 more
openaire   +2 more sources

Greater than the Sum: Applying Daily-Dose Equivalents to Antipsychotic Prescription Claims to Study Real-World Effects

open access: yesFrontiers in Pharmacology, 2021
Traditional methods to standardize exposures in pharmacoepidemiologic studies, like defined daily-doses, may be inadequate to capture drug class effects when there are many in-class medications, formulations, and administration routes.
Kaleen N. Hayes   +8 more
doaj   +1 more source

Histopathologic investigations of nifedipine-induced gingival hyperplasia in Wistar rats [PDF]

open access: yesVojnosanitetski Pregled, 2005
Background. Nifedipine, a calcium channel blocker, used in the therapy of cardiovascular diseases, can induce gingival overgrowth. The aim of the study was to assess the influence of nifedipine on the deeper periodontal tissues of the experimental ...
Brkić Zlata
doaj   +1 more source

The c.-1639g>A polymorphism of the VKORC1 gene and his influence on the therapeutic response during oral anticoagulants use [PDF]

open access: yesVojnosanitetski Pregled, 2009
Background/Aim. A single nucleotide polymorphism c.- 1639G>A in the promoter region of vitamin K-epoxide reductase (VKORC1) gene has been found to account for most of the variability in response to oral anticoagulants (OA). The aim of the study was to
Kovač Mirjana   +3 more
doaj   +1 more source

The relationship between tacrolimus concentration-dose ratio and genetic polymorphism in patients subjected to renal transplantation [PDF]

open access: yesVojnosanitetski Pregled, 2018
Background/Aim. Tacrolimus concentration-dose ratio as a potential therapeutic drug monitoring strategy was suggested to be used for the patients subjected to renal transplantation.
Rančić Nemanja   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy